Chronic Lymphocytic Leukemia (CLL) is a B-cell blood cancer that can take an indolent or accelerated course. Several new agents have been approved by the FDA for CLL treatment since November 2013, including Gazyva (obinutuzumab, Roche), Imbruvica (ibrutinib, PCYC & JNJ), and Zydelig (idelalisib, GILD). These new agents have high awareness among practicing oncologists and have the potential to sharply improve outcomes in some CLL patients.

This BioMedTracker infographic provides an overview of the epidemiology, recently approved drugs, late-stage pipeline, and historical revenues for CLL treatments.

To download a copy of this infographic, click on the link at the top of the page. Additional ASH- and oncology-related special reports available to BioMedTracker subscribers are linked at the bottom of the page.

For our disclosures, please read the BioMedTracker Research Standards.